2026-04-26T23:36:59Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/204222024-11-29T01:01:57Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Almeida, Antonio M
author
Prebet, Thomas
author
Itzykson, Raphael
author
Ramos, Fernando
author
Al-Ali, Haifa
author
Shammo, Jamile
author
Pinto, Ricardo
author
Maurillo, Luca
author
Wetzel, Jaime
author
Musto, Pellegrino
author
Van De Loosdrecht, Arjan A
author
Costa, Maria Joao
author
Esteves, Susana
author
Burgstaller, Sonja
author
Stauder, Reinhard
author
Autzinger, Eva M
author
Lang, Alois
author
Krippl, Peter
author
Geissler, Dietmar
author
Falantes, Jose F
author
Pedro, Carmen
author
Bargay Lleonart, Joan
author
Deben, Guillermo
author
Garrido, Ana
author
Bonanad, Santiago
author
Diez-Campelo, Maria
author
Thepot, Sylvain
author
Ades, Lionel
author
Sperr, Wolfgang R
author
Valent, Peter
author
Fenaux, Pierre
author
Sekeres, Mikkael A
author
Greil, Richard
author
Pleyer, Lisa
2024-07-11T09:07:44Z
2024-07-11T09:07:44Z
2017-04
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr;18(4):837.
http://hdl.handle.net/20.500.13003/9895
http://hdl.handle.net/20.500.12105/20422
28420120
10.3390/ijms18040837
1422-0067
International Journal of Molecular Sciences
2-s2.0-85018470782
402639400161
L615479846
Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
eng
Acute erythroleukemia
Azacitidine
Decitabine
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
research article